1. Holmes G. The symptoms of acute cerebellar injuries due to gunshot injuries. Brain. 1917;40:461-535.
2. Sullivan R, Yau WY, O’Connor E, Houlden H. Spinocerebellar ataxia: an update. J Neurol. 2019;266:533-544.
3. Jacobi H, Bauer P, Giunti P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow- up study. Neurology. 2011;77:1035-1041.
4. Zesiewicz TA, Greenstein PE, Sullivan KL, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology. 2012;78:545-550.
5. Romano S, Coarelli G, Marcotulli C, et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14:985-991.
6. Tsai YA, Liu RS, Lirng JF, et al. Treatment of spinocerebellar ataxia with mesenchymal stem cells: a phase I/IIa clinical study. Cell Transplant. 2017;26:503-512.
7. Trouillas P, Takayanagi T, Hallett M, et al. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci. 1997;145:205-211.
8. Schmitz-Hu¨ bsch T, Du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717-1720.
9. Yasui K, Yabe I, Yoshida K, et al. A 3-year cohort study of the natural history of spinocerebellar ataxia type 6 in Japan. Orphanet J Rare Dis. 2014;9:1-8.
10. Nakamura K, Yoshida K, Matsushima A, et al. Natural history of spinocerebellar ataxia type 31: a 4-year prospective study. Cerebellum. 2017;16:518-524.
11. Schmitz-Hu¨ bsch T, Du Montcel ST, Baliko L, et al. Reliability and validity of the international cooperative ataxia rating scale: a study in 156 spinocerebellar ataxia patients. Mov Disord. 2006;21:699-704.
12. Schmitz-Hu¨ bsch T, Giunti P, Stephenson DA, et al. SCA functional index: a useful compound performance measure for spinocerebellar ataxia. Neurology. 2008;71:486-492.
13. Du Montcel ST, Charles P, Ribai P, et al. Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. Brain. 2008;131:1352-1361.
14. Menegoni F, Milano E, Trotti C, et al. Quantitative evaluation of functional limitation of upper limb movements in subjects affected by ataxia. Eur J Neurol. 2009;16:232-239.
15. Ueda N, Hakii Y, Koyano S, et al. Quantitative analysis of upper-limb ataxia in patients with spinocerebellar degeneration. J Neurol. 2014;261:1381-1386.
16. Shirai S, Yabe I, Takahashi-Iwata I, et al. The responsiveness of triaxial accelerometer measurement of gait ataxia is higher than that of the scale for the assessment and rating of ataxia in the early stages of spinocerebellar degeneration. Cerebellum. 2019;18:721-730.
17. Honda T, Mitoma H, Yoshida H, et al. Assessment and rating of motor cerebellar ataxias with the Kinect v2 depth sensor: extending our appraisal. Front Neurol. 2020;11:1-14.
18. Mathiowetz V, Weber K, Kashman N, Volland G. Adult norms for the nine hole peg test of finger dexterity. Am J Occup Ther. 1985;5:24-38.
19. Chan YH. Biostatistics 304. Cluster Analysis. Singapore Med J. 2005;46:153-159.
20. Portney LG, Watkins MP. Foundations of Clinical Research: Applications to Practice. 3rd ed. Prentice Hall; 2009.
21. Tesio L. Outcome measurement in behavioural sciences: a view on how to shift attention from means to individuals and why. Int J Rehabil Res. 2012;35:1-12.
22. Middel B, Van Sonderen E. Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research. Int J Integr Care. 2002;2:e15.
23. Ashizawa T, Figueroa KP, Perlman SL, et al. Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J Rare Dis. 2013;8:177.
24. Schmitz-Hu¨ bsch T, Fimmers R, Rakowicz M, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology. 2010;74:678- 684.
25. Chan E, Charles P, Ribai P, et al. Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias. Mov Disord. 2011;26:534-538.
26. Franca MC Jr, D’Abreu A, Nucci A, et al. Progression of ataxia in patients with Machado-Joseph disease. Mov Disord. 2009;24:1387-1390.
27. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871-882.
28. Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology. 2005;64:1209-1214.
29. Payan CAM, Viallet F, Landwehrmeyer BG, et al. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS - PARKINSON PLUS SCALE. PLoS One. 2011;6:e22293.
30. Kimberlin CL, Winterstein AG. Validity and reliability of measurement instruments used in research. Am J Health Syst Pharm. 2008;65:2276-2284.
31. Lee YC, Liao YC, Wang PS, Lee IH, Lin KP, Soong BW. Comparison of cerebellar ataxias: a three-year prospective longitudinal assessment. Mov Disord. 2011;26:2081-2087.
32. D’Abreu A, Franca M, Lopes-Cendes I, Cendes F. The international cooperative ataxia rating scale in Machado- Joseph disease. Comparison with the unified multiple system atrophy rating scale. Mov Disord. 2007;22:1976-1979.
33. Matsumoto A, Asaga T, Tashiro K. Quantitative examination of cerebellar ataxia in the uppre limbs. Jpn J Rehabil Med. 1991;28:100-105.
34. Maurel N, Diop A, Gouelle A, Alberti C, Husson I. Assessment of upper limb function in young Friedreich ataxia patients compared to control subjects using a new three-dimensional kinematic protocol. Clin Biomech. 2013;28:386-394.
35. Jacobi H, Du Montcel ST, Bauer P, et al. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol. 2015;14:1101-1108.
36. Scho¨ ls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004;3:291-304.
37. Tada M, Yokoseki A, Onodera O. Overview of hereditary spinocerebellar ataxias in Japan. Brain Nerve. 2017;69: 879-890.
38. Schmitz-Hu¨ bsch T, Coudert M, Bauer P, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology. 2008;71:982-989.
39. Jacobi H, Hauser TK, Giunti P, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: the clinical spectrum of ataxia and morphometric brainstem and cerebellar findings. Cerebellum. 2012;11:155-166.
40. Hoche F, Guell X, Vangel MG, Sherman JC, Schmahmann JD. The cerebellar cognitive affective/Schmahmann syndrome scale. Brain. 2018;141:248-270.
41. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain. 1998;121:561-579.